COMMUNIQUÉS West-GlobeNewswire

Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy
16/04/2026
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today [...]
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
16/04/2026
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. BOSTON, April 16, 2026 ( [...]
Elicio Therapeutics Reports Inducement Grants
16/04/2026
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]
Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives
16/04/2026
FRISCO, Texas, April 16, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, today announced the appointment of Joy Rowan, MS, MBA to the role of [...]
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
16/04/2026
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage biopharmaceutical company developing drugs for the treatment of [...]
Totus Medicines to Present First-in-Class Covalent IRF5 Inhibitor Data at AAI IMMUNOLOGY2026
16/04/2026
First-in-class, covalent, oral small molecule inhibitor targeting IRF5 IRF5 is a genetically validated driver of autoimmune diseases, including systemic lupus erythematosus, Sjögren’s disease, and rheumatoid arthritis [...]
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
16/04/2026
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Nanox.ARC X Digital Advanced 3D imaging built for access and powered by innovation Wins 2026 Red Dot Award for Product Design
16/04/2026
International Red Dot Jury recognizes Nanox.ARC X for design excellence that brings advanced 3D tomosynthesis imaging into a wider range of clinical settings PETACH TIKVA, ISRAEL - 1 6 April , 2026 - Nanox Imaging Ltd [...]
SRx Health Solutions Acquires Shares of Compass Inc. and Increases Investment in Opendoor Technologies Inc.
16/04/2026
SRXH files Form S-4 with SEC in connection with EMJX merger SRXH provides update on performance through mid-April with an approximate 3.5% gain in hedging pool, driven by EMJX’s algorithm, and an approximate gain of 8% [...]
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
16/04/2026
BOCA RATON, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company focused on developing therapies that harness the patient’s innate immune system [...]
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
16/04/2026
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative [...]
ATUM Welcomes Gavin Barnard, Ph.D., as Chief Scientific Officer
16/04/2026
Newark, CALIFORNIA, April 16, 2026 (GLOBE NEWSWIRE) -- ATUM announced today the appointment of Gavin Barnard, Ph.D., as Chief Scientific Officer (CSO). In this role, Dr. Barnard will lead ATUM’s scientific strategy and [...]
MIMEDX Announces Restructuring and Cost Reduction Initiative
16/04/2026
Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost [...]
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
16/04/2026
TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
Achieve Life Sciences Announces Up to $354 Million Private Placement
16/04/2026
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, [...]
Helsinn appoints Giacomo Braglia to the Board of Directors
16/04/2026
Lugano, Switzerland – April 16 th , 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, is pleased to announce the appointment of [...]
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
16/04/2026
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up [...]
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros
16/04/2026
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros Lille, le 16 avril 2026 - Roquette, un leader mondial des ingrédients d'origine végétale et un fournisseur majeur d’ [...]

Pages